Targeting ALK in neuroblastoma—preclinical and clinical advancements

Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.

(2017) D. Weiser et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Induced Apoptosis in a Transgenic Model of Neuroblastoma Proceeds Through p53 Induction

(2015) Louis Chesler et al.   NEOPLASIA

Enhanced Antitumorigenic Effects in Glioblastoma on Double Targeting of Pleiotrophin and Its Receptor ALK

(2015) Marius Grzelinski et al.   NEOPLASIA

Identification of Oncogenic Point Mutations and Hyperphosphorylation of Anaplastic Lymphoma Kinase in Lung Cancer

(2015) Yi-Wei Wang et al.   NEOPLASIA

The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo

(2014) Christina Schönherr et al.   Translational Oncology

Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma

(2012) Mangeng Cheng et al.   Anti-Cancer Agents in Medicinal Chemistry

Clonal evolution in cancer

(2012) Mel Greaves et al.   NATURE

Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma

(2012) Y. H. Chanthery et al.   Science Translational Medicine

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684

(2011) Christina Schönherr et al.   BIOCHEMICAL JOURNAL

Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study

(2011) Jane E. Minturn et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma

(2011) Robin E. Norris et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene

(2011) A. K. Murugan et al.   CANCER RESEARCH

High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma

(2011) J. H. Schulte et al.   CLINICAL CANCER RESEARCH

Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications

(2011) J. Carlijn van Gaal et al.   JOURNAL OF CLINICAL ONCOLOGY

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

(2011) A. Faisal et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Models for Neuroblastoma: Establishing a Baseline for Treatment

(2011) Tal Teitz et al.   PLoS One

miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs

(2011) Marta Terrile et al.   PLoS One

Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

(2011) S. C. Bresler et al.   Science Translational Medicine

Genetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma

(2011) Louis Chesler et al.   SEMINARS IN CANCER BIOLOGY

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels

(2011) Floor A. M. Duijkers et al.   CELLULAR ONCOLOGY

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

(2010) Christian C. Lee et al.   BIOCHEMICAL JOURNAL

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

(2010) Roberto T. Bossi et al.   BIOCHEMISTRY

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

(2010) T. Sasaki et al.   CANCER RESEARCH

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

(2010) S. De Brouwer et al.   CLINICAL CANCER RESEARCH

The biology and treatment of EML4-ALK non-small cell lung cancer

(2010) Takaaki Sasaki et al.   EUROPEAN JOURNAL OF CANCER

Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century

(2010) Malcolm A. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Towards patient-based cancer therapeutics

(2010) Stuart L Schreiber et al.   NATURE BIOTECHNOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

(2010) S. Buonamici et al.   Science Translational Medicine

Anaplastic lymphoma kinase: signalling in development and disease

(2009) Ruth H. Palmer et al.   BIOCHEMICAL JOURNAL

The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways

(2009) M. S. Lim et al.   BLOOD

Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients

(2009) L. Passoni et al.   CANCER RESEARCH

Inhibition of ALK Signaling for Cancer Therapy

(2009) Y. P. Mosse et al.   CLINICAL CANCER RESEARCH

Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas

(2009) Olesya Chayka et al.   JNCI-Journal of the National Cancer Institute

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

(2008) Helena Carén et al.   BIOCHEMICAL JOURNAL

Risk Stratification in Cancer Predisposition Syndromes: Lessons Learned from Novel Molecular Developments in Li-Fraumeni Syndrome

(2008) U. Tabori et al.   CANCER RESEARCH

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH

ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

(2008) M. D. Hogarty et al.   CANCER RESEARCH

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

(2008) Jeffrey A Engelman et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design

(2008) Jeffrey M. Skolnik et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

(2008) M Scaltriti et al.   ONCOGENE

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

(2007) John M. Maris et al.   PEDIATRIC BLOOD & CANCER